

Application No.: 09/975,136


2

Docket No.: 200220061.00

AMENDMENTS TO THE CLAIMS

Claims 1-4 (Canceled).

Claim ~~5~~¹ (Currently Amended): A method for treating or preventing ~~a disease or disorder caused by~~ *Helicobacter pylori* (*H. pylori*) infection in a subject, which method comprises administering, to a subject ~~to~~ for which such treatment or prevention is needed or desirable, an effective amount of ~~the~~ a compound of claim 1 having the following formula I:



wherein n is 0 or 1, and R is selected from the group consisting of C₁₋₁₀ alkyl, C₆₋₁₀ aryl and




and wherein when n is 0, R is not C₆₋₁₀ aryl, or a pharmaceutically acceptable salt thereof, thereby said ~~disease or disorder~~ infection is treated or prevented.

Claim ~~5~~² (Original): The method of claim ~~5~~¹, wherein the subject is a mammal.


Claim ~~5~~³ (Original): The method of claim ~~5~~², wherein the mammal is a human.

Claim ~~5~~⁴ (Previously Amended): The method of claim ~~5~~¹, which comprises administering a compound having the following formula II:



or a pharmaceutically acceptable salt thereof, to the subject.

Claim ~~5~~⁵ (Previously Amended): The method of claim ~~5~~¹, which comprises administering a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, having the following formula I:



sd-170254

Application No.: 09/975,136

3

Docket No.: 524022000100

wherein n is 0 or 1, and R is selected from the group consisting of C₁₋₁₀ alkyl, C₆₋₁₀ aryl and



and wherein when n is 0, R is not C₆₋₁₀ aryl,
to the subject.

FI cont. Claim ~~10~~⁶ (Currently Amended): The method of claim ~~5~~¹, wherein ~~the~~ a disease or disorder caused by *H. pylori* infection to be treated or prevented is chronic gastritis, gastroduodenal ulcer, adenocarcinoma of the distal stomach, gastric lymphoma or gastric cancer.

Claim ~~11~~⁷ (Original): The method of claim ~~5~~¹, wherein the subject is treated without administering an anti-*H. pylori* agent.


Claim ~~12~~⁸ (Currently Amended): The method of claim ~~11~~⁷, wherein the anti-*H. pylori* agent is a proton-pump inhibitor (PPI), metronidazole, clarithromycin or amoxicillin.

Claim ~~13~~⁹ (Original): The method of claim ~~5~~¹, wherein the *H. pylori* is a resistant strain induced by PPI, metronidazole, clarithromycin or amoxicillin treatment.

Claim ~~14~~¹⁰ (Original): The method of claim ~~5~~¹, wherein the compound or a pharmaceutically acceptable salt thereof is administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, oral administration, or topical administration.

Claim ~~15~~¹¹ (Previously Amended): The method of claim ~~5~~¹, which further comprises a step of diagnosis or prognosis of *H. pylori* infection in the subject.

Claim ~~16~~¹² (Currently Amended): A composition, which composition comprises the a compound of claim 1, having the following formula I:




sd-170254

Application No.: 09/975,136

4

Docket No.: 524022000100

wherein n is 0 or 1, and R is selected from the group consisting of C₁₋₁₀ alkyl, C₆₋₁₀ aryl and



and wherein when n is 0, R is not C₆₋₁₀ aryl, or a pharmaceutically acceptable salt thereof, and an anti-*H. pylori* agent.

13
Claim 17 (Previously Amended): The composition of claim 16, wherein the anti-*H. pylori* agent is PPI, metronidazole, clarithromycin or amoxicillin.


14
Claim 18 (Currently Amended): A method for treating or preventing a ~~disease or disorder~~ caused by *H. pylori* infection in a subject, which method comprises administering, to a subject to for which such treatment or prevention is needed or desirable, an effective amount of the composition of claim 16, or a pharmaceutically acceptable salt thereof, thereby said ~~disease or disorder~~ infection is treated or prevented.

15
[Claim 19 (Canceled).

16
Claim 20 (Currently Amended): A kit, which kit comprises the composition of claim 16, and an instruction for using said composition in treating or preventing a ~~disease or disorder~~ caused by *H. pylori* infection in a subject.

17
[Claim 21 (Canceled).

18
Claim 22 (New): A compound, which has the following formula II:



or a pharmaceutically acceptable salt thereof.

sd-170254

Application No.: 09/975,136

5

Docket No.: 524022000100

Claim ~~23~~¹⁵ (New): A pharmaceutical composition, which composition comprises the compound of claim ~~22~~¹⁰ and a pharmaceutically acceptable carrier or excipient.

~~Claim 24~~ (New): A kit, which kit comprises the compound of claim ~~22~~, or a pharmaceutically acceptable salt thereof, and an instruction for using said compound or pharmaceutically acceptable salt in treating or preventing *H. pylori* infection in a subject.

sd-170254

4